CeriBell, Inc.·Healthcare
CeriBell (NASDAQ: CBLL) executives outlined the company's 2026 priorities and growth drivers during a fireside chat at the 46th annual TD Cowen Healthcare Conference, emphasizing continued expansion in hospital adoption, upcoming pediatric and neonatal offerings, early plans for a delirium commercialization pilot, and efforts to maintain strong gross margins amid shifting tariff dynamics. 2026 outlook and
CeriBell (NASDAQ: CBLL) is seeking to accelerate adoption of its point-of-care EEG platform in U.S. hospitals while expanding into new patient populations and indications, Chief Financial Officer Scott Blumberg said at the 47th Annual Raymond James Institutional Investors Conference. Blumberg told investors the company ended 2025 with $89 million in revenue, representing 36% year-over-year growth, and
Shares of CeriBell, Inc. (NASDAQ: CBLL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the
CeriBell (NASDAQ: CBLL - Get Free Report) and Allurion Technologies (NYSE: ALUR - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Analyst Recommendations This is a breakdown of recent
CeriBell (NASDAQ: CBLL - Get Free Report) and Nephros (NASDAQ: NEPH - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings. Insider and Institutional Ownership 41.1% of Nephros shares are
CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
